Fundsters interested in health care investing should take a look at the Monday Wall Street Journal
Fund Track. Citing a Morningstar
survey, the Journal praised
the strong performance of Manning & Napier Life Sciences
compared to competitors this year.
The fund has risen from its three-year negative slump, pulling in an 18 percent return for the year to date, according to Morningstar. The Journal attributed Manning & Napier's performance to its investment strategy of small- to mid-sized capitalization in health-care stocks from equipment and supplies to service providers.
Manning & Napier has also stayed away from large pharmaceuticals and drug stocks, which have "generally underperformed" this year, wrote the Journal. This has helped clear the fund's balance sheet from the heavy-hitting losses that some of its competitors have faced.
Stay ahead of the news ... Sign up for our email alerts now